EBS Emergent BioSolutions Inc. logo

EBS Emergent BioSolutions Inc.

Healthcare
$9.13+0.00%OpenMarket Cap: $471.1M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

7.83

PEG

0.06

P/B

0.84

P/S

0.64

EV/EBITDA

5.10

DCF Value

$2.66

FCF Yield

31.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

44.4%

Operating Margin

10.5%

Net Margin

-1.3%

ROE

-1.6%

ROA

-0.7%

ROIC

-14.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$156.1M$6.8M$
Q4 null$148.7M$-54.6M$
FY null$742.9M$52.6M$
Q3 null$231.1M$51.2M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-03-09
HC Wainwright & Co.Buy
2025-12-16
HC Wainwright & Co.Buy
2025-09-03

Trading Activity

Insider Trades

View All
Katkin Keithdirector
SellMon May 04
Katkin Keithdirector
SellMon May 04
DeGolyer Donald Wdirector
SellMon May 04
DeGolyer Donald Wdirector
SellMon May 04
DeGolyer Donald Wdirector
SellMon May 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.33

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Peers